Issue: 2026, Vol. 31, No. 3

A. A. Koklyushkina, I. G. Sitnikov, M. S. Bokhonov

RISK CRITERIA FOR THE DEVELOPMENT OF METABOLIC SYNDROME IN PATIENTS WITH CHRONIC HEPATITIS C

Keywords

hepatitis C, chronic hepatitis C, metabolic syndrome, comorbid pathology, PON1 gene, LPL gene

Abstarct

Objective – to develop a simplified method for predicting the development of metabolic syndrome in patients with chronic hepatitis C based on clinical, laboratory, and genetic profile parameters. Materials and Methods. 240 patients with chronic hepatitis C (aged 18–60 years) were examined between 2022 and 2025. The diagnosis was verified by the detection of HCV RNA. Metabolic syndrome was diagnosed based on the presence and severity of abdominal obesity, arterial hypertension, dyslipidemia, and hyperglycemia. A molecular genetic study of LPL (S447X) and PON1 (Q192R) gene polymorphisms was conducted. Statistical processing included logistic regression analysis with stepwise selection and ROC analysis. Results and Discussion. Metabolic syndrome was identified in 124 patients and was absent in 116. In the group of patients with metabolic syndrome, men predominated, they were older, and arterial hypertension, type 2 diabetes mellitus, and obesity were more frequently registered (p < 0.05). The multifactorial model included significant predictors: body mass index (OR = 1.86), presence of arterial hypertension (OR = 39.29), very low-density lipoprotein level (OR = 4.48), blood glucose (OR = 2.27), CC genotype of the LPL S447X gene (OR = 17.19), and QR genotype of the PON1 Q192R gene (OR = 0.20). The model demonstrated high predictive ability: sensitivity – 0.944, specificity – 0.940, area under the ROC curve – 0.942. A formula was developed for the quantitative calculation of the probability of developing metabolic syndrome with a threshold value of p ≥ 0.388. Conclusion. The proposed method allows for highly accurate prediction of the risk of developing metabolic syndrome in patients with chronic hepatitis C, taking into account the individual genetic profile, which ensures a personalized approach to the diagnosis and treatment of this category of patients. The developed method is protected by RF Patent No. 2862798.

Скачать

• Quid est Veritas_3_31_2026-16-22